These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21907108)

  • 21. Target class strategies in mass spectrometry-based proteomics.
    Opiteck GJ; Scheffler JE
    Expert Rev Proteomics; 2004 Jun; 1(1):57-66. PubMed ID: 15966799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical chemistry devices; classification of the biotinidase test system. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Mar; 65(61):16520-1. PubMed ID: 11010644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?
    Hill MM; Mollee PN
    Expert Rev Proteomics; 2017 Jul; 14(7):565-566. PubMed ID: 28438056
    [No Abstract]   [Full Text] [Related]  

  • 25. An experimental correction for arginine-to-proline conversion artifacts in SILAC-based quantitative proteomics.
    Van Hoof D; Pinkse MW; Oostwaard DW; Mummery CL; Heck AJ; Krijgsveld J
    Nat Methods; 2007 Sep; 4(9):677-8. PubMed ID: 17762871
    [No Abstract]   [Full Text] [Related]  

  • 26. Counterpoint: Food and Drug Administration guidance for C-reactive protein assays: matching claims with performance data.
    Callaghan JV; Gutman SI
    Clin Chem; 2006 Jul; 52(7):1256-7. PubMed ID: 16798965
    [No Abstract]   [Full Text] [Related]  

  • 27. mzIdentML: an open community-built standard format for the results of proteomics spectrum identification algorithms.
    Eisenacher M
    Methods Mol Biol; 2011; 696():161-77. PubMed ID: 21063947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular diagnostics: an FDA perspective.
    Ardekani AM; Petricoin EF; Hackett JL
    Expert Rev Mol Diagn; 2003 Mar; 3(2):129-40. PubMed ID: 12647991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteoform Analysis to Fulfill Unmet Clinical Needs and Reach Global Standardization of Protein Measurands in Clinical Chemistry Proteomics.
    van der Burgt YEM; Cobbaert CM
    Clin Lab Med; 2018 Sep; 38(3):487-497. PubMed ID: 30115393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker validation by targeted mass spectrometry.
    McIntosh M; Fitzgibbon M
    Nat Biotechnol; 2009 Jul; 27(7):622-3. PubMed ID: 19587666
    [No Abstract]   [Full Text] [Related]  

  • 31. US Food and Drug Administration Perspectives on Clinical Mass Spectrometry.
    Lathrop JT; Jeffery DA; Shea YR; Scholl PF; Chan MM
    Clin Chem; 2016 Jan; 62(1):41-7. PubMed ID: 26553791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical devices; clinical chemistry and clinical toxicology devices; classification of sirolimus test system devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Sep; 69(189):58258-60. PubMed ID: 15457610
    [No Abstract]   [Full Text] [Related]  

  • 33. Medical devices; exemption from premarket notification; class II devices; triiodothyronine test system. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(202):62285-6. PubMed ID: 11503681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ICPL--isotope-coded protein label.
    Kellermann J
    Methods Mol Biol; 2008; 424():113-23. PubMed ID: 18369857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing an understanding of proteomics: an introduction to biological mass spectrometry.
    Koomen J; Hawke D; Kobayashi R
    Cancer Invest; 2005; 23(1):47-59. PubMed ID: 15779868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Point: high-sensitivity C-reactive protein and cardiac C-reactive protein assays: is there a need to differentiate?
    Rifai N; Ballantyne CM; Cushman M; Levy D; Myers GL
    Clin Chem; 2006 Jul; 52(7):1254-6. PubMed ID: 16798964
    [No Abstract]   [Full Text] [Related]  

  • 37. Mass spectrometry-based quantitative proteomics.
    Heck AJ; Krijgsveld J
    Expert Rev Proteomics; 2004 Oct; 1(3):317-26. PubMed ID: 15966828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum proteomic profiling in patients with bladder cancer.
    Schwamborn K; Krieg RC; Grosse J; Reulen N; Weiskirchen R; Knuechel R; Jakse G; Henkel C
    Eur Urol; 2009 Dec; 56(6):989-96. PubMed ID: 19282097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using cross-correlation normalized for peptide length to optimize peptide identification in shotgun proteomics.
    Yang B; Ying W; Gong Y; Zhang Y; Cai Y; Dong H; Qian X
    Rapid Commun Mass Spectrom; 2005; 19(20):2983-5. PubMed ID: 16178048
    [No Abstract]   [Full Text] [Related]  

  • 40. Classification of Samples with Order-Restricted Discriminant Rules.
    Conde D; Fernández MA; Salvador B; Rueda C
    Methods Mol Biol; 2016; 1362():159-74. PubMed ID: 26519176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.